Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atopic Hypersensitivity Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

NCT04065633
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
P3-Fast, Comm-Fast, Vari-Fast, Comm-Fed
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 20, 2026, 10:53 AM EDT
Completed No phase listed Observational

A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients

NCT01714245
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
TopMD Skin Care, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 20, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, JNJ-95475939, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03349060
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 20, 2026, 10:53 AM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

NCT03706040
View directory record Official record
Conditions
Dermatitis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

NCT00789880
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Emollient Therapy on the Skin Barrier

NCT01291940
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Pediatric Moisturizer, Adult Moisturizer
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Months to 99 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

NCT01660217
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
A written Eczema Action Plan (EAP)
Other
Lead sponsor
Dermatology & Aesthetics of Wicker Park
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 20, 2026, 10:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes

NCT04965233
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, DNA
Interventions
DNA reports, Information reports
Behavioral
Lead sponsor
Studies&Me
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 20, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 20, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

NCT00076375
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Nanocrystalline silver cream (NPI)
Drug
Lead sponsor
Nucryst Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 20, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional

Topical Treatment for Atopic Dermatitis

NCT06244212
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Cutivate Lotion HPA Axis Pediatric Study

NCT00546000
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluticasone propionate 0.05% lotion
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months to 12 Months
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Poway, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 20, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normal Blood, Bone Marrow and Buccal Mucosa Protocol

NCT00806364
View directory record Official record
Conditions
Non-atopic, Atopic, Healthy, Normal, Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 20, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

NCT03379311
View directory record Official record
Conditions
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Palo Alto, California • Edgewater, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 20, 2026, 10:53 AM EDT